Lauren P. Pommert

Hematology | Oncology
3333 Burnet Ave
Cincinnati, OH 45229

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 30 publications

Real-world experience with IDH inhibitors in pediatric patients with IDH1- and IDH2-mutated acute myeloid leukemia and myelodysplastic syndrome.

Real-world experience with IDH inhibitors in pediatric patients with IDH1- and IDH2-mutated acute myeloid leukemia and myelodysplastic syndrome.

Journal: Haematologica
Published: May 12, 2026

CPX-351 in High-Risk Relapsed Pediatric Acute Leukemia: Real-World Phase 1 Data Establishing the FDA-Approved Dose.

CPX-351 in High-Risk Relapsed Pediatric Acute Leukemia: Real-World Phase 1 Data Establishing the FDA-Approved Dose.

Journal: Pediatric blood & cancer
Published: February 24, 2026

Lymphoid malignancies in patients with Shwachman-Diamond syndrome.

Lymphoid malignancies in patients with Shwachman-Diamond syndrome.

Journal: Blood
Published: August 19, 2024

Shining a TORCH on a Case of Blueberry Muffin Rash in a Newborn Infant.

Shining a TORCH on a Case of Blueberry Muffin Rash in a Newborn Infant.

Journal: NeoReviews
Published: June 10, 2024

Clinical outcomes of hypomethylating agents and venetoclax in newly diagnosed unfit and relapsed/refractory paediatric, adolescent and young adult acute myeloid leukaemia patients.

Clinical outcomes of hypomethylating agents and venetoclax in newly diagnosed unfit and relapsed/refractory paediatric, adolescent and young adult acute myeloid leukaemia patients.

Journal: British journal of haematology
Published: June 04, 2024

A case of co-occurring acute myeloid leukemia and relapsed diffuse large B-cell lymphoma in a young adult with Shwachman-Diamond syndrome.

A case of co-occurring acute myeloid leukemia and relapsed diffuse large B-cell lymphoma in a young adult with Shwachman-Diamond syndrome.

Journal: Pediatric blood & cancer
Published: April 29, 2024

Optimizing early phase clinical trial washout periods: a report from the Therapeutic Advances in Childhood Leukemia and Lymphoma consortium.

Optimizing early phase clinical trial washout periods: a report from the Therapeutic Advances in Childhood Leukemia and Lymphoma consortium.

Journal: Journal of the National Cancer Institute
Published: April 05, 2024

Toxicity profile of high-dose methotrexate in young children with central nervous system tumors.

Toxicity profile of high-dose methotrexate in young children with central nervous system tumors.

Journal: Pediatric blood & cancer
Published: April 03, 2024

Real-world use of tisagenlecleucel in children and young adults with relapsed or refractory B-cell lymphomas.

Real-world use of tisagenlecleucel in children and young adults with relapsed or refractory B-cell lymphomas.

Journal: Blood advances
Published: February 16, 2024

Clinical covariates that improve the description of high dose methotrexate pharmacokinetics in a diverse population to inform MTXPK.org.

Clinical covariates that improve the description of high dose methotrexate pharmacokinetics in a diverse population to inform MTXPK.org.

Journal: Clinical and translational science
Published: April 18, 2023

The evolution of targeted therapy in pediatric AML: gemtuzumab ozogamicin, FLT3/IDH/BCL2 inhibitors, and other therapies.

The evolution of targeted therapy in pediatric AML: gemtuzumab ozogamicin, FLT3/IDH/BCL2 inhibitors, and other therapies.

Journal: Hematology. American Society of Hematology. Education Program
Published: December 09, 2022

Patients with Down syndrome can be included in early phase clinical trials- a report from the T2016-003 Therapeutic Advances in Childhood Leukemia and Lymphoma (TACL) study.

Patients with Down syndrome can be included in early phase clinical trials- a report from the T2016-003 Therapeutic Advances in Childhood Leukemia and Lymphoma (TACL) study.

Journal: Leukemia
Published: October 02, 2022
Showing 1-12 of 30

Last Updated: 09/26/2026